Cargando…

Evaluation of DNA Methylation Array for Glioma Tumor Profiling and Description of a Novel Epi-Signature to Distinguish IDH1/IDH2 Mutant and Wild-Type Tumors

Molecular biomarkers, such as IDH1/IDH2 mutations and 1p19q co-deletion, are included in the histopathological and clinical criteria currently used to diagnose and classify gliomas. IDH1/IDH2 mutation is a common feature of gliomas and is associated with a glioma-CpG island methylator phenotype (CIM...

Descripción completa

Detalles Bibliográficos
Autores principales: Schenkel, Laila C., Mathew, Joseph, Hirte, Hal, Provias, John, Paré, Guillaume, Chong, Michael, Grafodatskaya, Daria, McCready, Elizabeth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9690723/
https://www.ncbi.nlm.nih.gov/pubmed/36360312
http://dx.doi.org/10.3390/genes13112075
_version_ 1784836863359451136
author Schenkel, Laila C.
Mathew, Joseph
Hirte, Hal
Provias, John
Paré, Guillaume
Chong, Michael
Grafodatskaya, Daria
McCready, Elizabeth
author_facet Schenkel, Laila C.
Mathew, Joseph
Hirte, Hal
Provias, John
Paré, Guillaume
Chong, Michael
Grafodatskaya, Daria
McCready, Elizabeth
author_sort Schenkel, Laila C.
collection PubMed
description Molecular biomarkers, such as IDH1/IDH2 mutations and 1p19q co-deletion, are included in the histopathological and clinical criteria currently used to diagnose and classify gliomas. IDH1/IDH2 mutation is a common feature of gliomas and is associated with a glioma-CpG island methylator phenotype (CIMP). Aberrant genomic methylation patterns can also be used to extrapolate information about copy number variation in a tumor. This project’s goal was to assess the feasibility of DNA methylation array for the simultaneous detection of glioma biomarkers as a more effective testing strategy compared to existing single analyte tests. Methods: Whole-genome methylation array (WGMA) testing was performed using 48 glioma DNA samples to detect methylation aberrations and chromosomal gains and losses. The analyzed samples include 39 tumors in the discovery cohort and 9 tumors in the replication cohort. Methylation profiles for each sample were correlated with IDH1 p.R132G mutation, immunohistochemistry (IHC), and previous 1p19q clinical testing to assess the sensitivity and specificity of the WGMA assay for the detection of these variants. Results: We developed a DNA methylation signature to specifically distinguish a IDH1/IDH2 mutant tumor from normal samples. This signature is composed of 11 CpG sites that were significantly hypermethylated in the IDH1/IDH2 mutant group. Copy number analysis using WGMA data was able to identify five of five positive samples for 1p19q co-deletion and was concordant for all negative samples. Conclusions: The DNA methylation signature presented here has the potential to refine the utility of WGMA to predict IDH1/IDH2 mutation status of gliomas, thus improving diagnostic yield and efficiency of laboratory testing compared to single analyte IDH1/IDH2 or 1p19q tests.
format Online
Article
Text
id pubmed-9690723
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96907232022-11-25 Evaluation of DNA Methylation Array for Glioma Tumor Profiling and Description of a Novel Epi-Signature to Distinguish IDH1/IDH2 Mutant and Wild-Type Tumors Schenkel, Laila C. Mathew, Joseph Hirte, Hal Provias, John Paré, Guillaume Chong, Michael Grafodatskaya, Daria McCready, Elizabeth Genes (Basel) Article Molecular biomarkers, such as IDH1/IDH2 mutations and 1p19q co-deletion, are included in the histopathological and clinical criteria currently used to diagnose and classify gliomas. IDH1/IDH2 mutation is a common feature of gliomas and is associated with a glioma-CpG island methylator phenotype (CIMP). Aberrant genomic methylation patterns can also be used to extrapolate information about copy number variation in a tumor. This project’s goal was to assess the feasibility of DNA methylation array for the simultaneous detection of glioma biomarkers as a more effective testing strategy compared to existing single analyte tests. Methods: Whole-genome methylation array (WGMA) testing was performed using 48 glioma DNA samples to detect methylation aberrations and chromosomal gains and losses. The analyzed samples include 39 tumors in the discovery cohort and 9 tumors in the replication cohort. Methylation profiles for each sample were correlated with IDH1 p.R132G mutation, immunohistochemistry (IHC), and previous 1p19q clinical testing to assess the sensitivity and specificity of the WGMA assay for the detection of these variants. Results: We developed a DNA methylation signature to specifically distinguish a IDH1/IDH2 mutant tumor from normal samples. This signature is composed of 11 CpG sites that were significantly hypermethylated in the IDH1/IDH2 mutant group. Copy number analysis using WGMA data was able to identify five of five positive samples for 1p19q co-deletion and was concordant for all negative samples. Conclusions: The DNA methylation signature presented here has the potential to refine the utility of WGMA to predict IDH1/IDH2 mutation status of gliomas, thus improving diagnostic yield and efficiency of laboratory testing compared to single analyte IDH1/IDH2 or 1p19q tests. MDPI 2022-11-09 /pmc/articles/PMC9690723/ /pubmed/36360312 http://dx.doi.org/10.3390/genes13112075 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Schenkel, Laila C.
Mathew, Joseph
Hirte, Hal
Provias, John
Paré, Guillaume
Chong, Michael
Grafodatskaya, Daria
McCready, Elizabeth
Evaluation of DNA Methylation Array for Glioma Tumor Profiling and Description of a Novel Epi-Signature to Distinguish IDH1/IDH2 Mutant and Wild-Type Tumors
title Evaluation of DNA Methylation Array for Glioma Tumor Profiling and Description of a Novel Epi-Signature to Distinguish IDH1/IDH2 Mutant and Wild-Type Tumors
title_full Evaluation of DNA Methylation Array for Glioma Tumor Profiling and Description of a Novel Epi-Signature to Distinguish IDH1/IDH2 Mutant and Wild-Type Tumors
title_fullStr Evaluation of DNA Methylation Array for Glioma Tumor Profiling and Description of a Novel Epi-Signature to Distinguish IDH1/IDH2 Mutant and Wild-Type Tumors
title_full_unstemmed Evaluation of DNA Methylation Array for Glioma Tumor Profiling and Description of a Novel Epi-Signature to Distinguish IDH1/IDH2 Mutant and Wild-Type Tumors
title_short Evaluation of DNA Methylation Array for Glioma Tumor Profiling and Description of a Novel Epi-Signature to Distinguish IDH1/IDH2 Mutant and Wild-Type Tumors
title_sort evaluation of dna methylation array for glioma tumor profiling and description of a novel epi-signature to distinguish idh1/idh2 mutant and wild-type tumors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9690723/
https://www.ncbi.nlm.nih.gov/pubmed/36360312
http://dx.doi.org/10.3390/genes13112075
work_keys_str_mv AT schenkellailac evaluationofdnamethylationarrayforgliomatumorprofilinganddescriptionofanovelepisignaturetodistinguishidh1idh2mutantandwildtypetumors
AT mathewjoseph evaluationofdnamethylationarrayforgliomatumorprofilinganddescriptionofanovelepisignaturetodistinguishidh1idh2mutantandwildtypetumors
AT hirtehal evaluationofdnamethylationarrayforgliomatumorprofilinganddescriptionofanovelepisignaturetodistinguishidh1idh2mutantandwildtypetumors
AT proviasjohn evaluationofdnamethylationarrayforgliomatumorprofilinganddescriptionofanovelepisignaturetodistinguishidh1idh2mutantandwildtypetumors
AT pareguillaume evaluationofdnamethylationarrayforgliomatumorprofilinganddescriptionofanovelepisignaturetodistinguishidh1idh2mutantandwildtypetumors
AT chongmichael evaluationofdnamethylationarrayforgliomatumorprofilinganddescriptionofanovelepisignaturetodistinguishidh1idh2mutantandwildtypetumors
AT grafodatskayadaria evaluationofdnamethylationarrayforgliomatumorprofilinganddescriptionofanovelepisignaturetodistinguishidh1idh2mutantandwildtypetumors
AT mccreadyelizabeth evaluationofdnamethylationarrayforgliomatumorprofilinganddescriptionofanovelepisignaturetodistinguishidh1idh2mutantandwildtypetumors